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Incomplete brain tumor removal always causes neurologic deficit, disease recurrence and high 
mortality. Protoporphyrin IX (PpIX) accumulated in glioma cells with exogenous 5-aminolevulinic 
acid (5-ALA) serves as contrast agent for fluorescence-guided surgery and as well as acts as a 
photosensitizer for photodynamic therapy (PDT). However, the accurate tumor delineation using 
PpIX is limited by autofluorescence and superficial penetration depth. LS301 is a tumor-targeted 
near-infrared (NIR) contrast agent developed in our lab which allows deeper tumor imaging and 
avoids autofluorescence. My project aims to investigate whether LS301 can improve PpIX mediated 
PDT and tumor removal surgery. We have demonstrated co-localization of LS301 and PpIX in 
DBT and U87-MG glioma cell lines and are currently testing the effect of LS301 on PpIX mediated 
PDT in vitro. We will also compare LS301-PpIX with PpIX only PDT and tumor removal in mouse 
models of brain cancer. This study can potentially increase efficacy of PDT and fluorescence-guided 
brain tumor resection.
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Chapter 1 
 
Introduction 
 
1.1 Brain cancer and conventional brain tumor 
removal surgery 
 
Brian cancer is one of the top ten leading cause of cancer death in the United States [1]. From the 
2017 cancer statistics, brain and other nervous system cancer account for 3% of all cases in men and 
women, respectively [1]. Moreover, relative five-year survival for brain cancer has hardly improved 
for thirty years and the survival rate for all malignant brain tumor patients is only 30% [1]. 
Particularly, the survival rate for the most common form of primary malignant brain tumors, 
glioblastoma, is only 5.5% [1]. In addition, brain cancer also represents 20% of all cancer cases in 
child [2]. In most recent surveys, brain cancer is the leading cause cancer death in children (0-14 
years old age) [3]. There are many methods to treat brain tumor and brain tumor removal surgery is 
one modality. The application of image guidance system is prevailing in brain tumor removal surgery. 
Conventionally, brain tumor surgery with image guidance system still uses surgery microscope 
shown in Fig 1.1 [4]. Surgery microscope is a high-cost and huge installation in the operation room. 
And the surgery microscope is difficult to be rotated and twisted with the movement of surgeon’s 
head, thereby some tumors cannot be found and removed during the surgery, especially those 
diffuse tumor and boundary tumor cells surrounded by healthy tissue [4]. Instead, incomplete tumor 
removal during surgery can cause local cancer recurrence, paralysis, low intelligence quotient and 
high mortality in brain tumor patients. Thus, improving the extent of tumor resection may increase 
long term survival and decrease the need for radiation and chemotherapy along with its harmful 
side-effects. One strategy to improve tumor resection is to use real-time fluorescence image 
guidance. 
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Figure 1.1 surgery microscope in operation room 
1.2 Binocular goggle augmented imaging system 
 
To identify microscopic tumors, Dr. Samuel Achilefu and Optical Radiology lab has developed a 
wearable binocular goggle augmented imaging and navigation system (GAINS) [5]. GAINS provides 
more accurate intraoperative visualization of tumors to improve surgical outcomes and reduce the 
rate of surgery repeats. With the application of real-time fluorescent image system, GAINS can 
quickly produce images and allow surgeons to visualize and distinguish the marginal and diffuse 
tumors from healthy tissues [5]. Besides, GAINS can mitigate the difficulties and inconvenience of 
surgery microscope in brain tumor removal surgery. The wearable goggle imaging system is 
demonstrated in Fig 1.2 [5]. 
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Figure 1. 2 Wearable goggle imaging system 
1.3 5-Aminoleulinic acid (5-ALA) and LS301 in 
clinical use 
 
A contrast agent is necessary for fluorescence image guided surgery.  Protoporphyrin IX (PpIX) is 
the metabolism product of  5-Aminoleulinc acid (5-ALA) in heme biosynthesis pathway serving as a 
fluorophore compound when excited by appropriate excitation light[6]. The heme biosynthesis 
pathway is illustrated in fig 1.3 [6]. 
 
Figure 1.3 Metabolic pathway of 5-ALA 
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Figure 1.4 Schematic representation of clinical use of 5-ALA 
 
PpIX is particularly accumulated in heme biosynthesis pathway because the inactivity of 
ferrochelatase , in tumor cells. Ferrochelatase is the crucial enzyme at the final step of the heme 
biosynthesis [6]. 5-aminoleulinc acid (5-ALA) has been approved in Europe for high grade brain 
tumor, such as glioblastoma. PpIX fluorescence has been not only used for intraoperative contrast 
under blue light for malignant glioma but also be used as a photosensitizer for photodynamic 
therapy (PDT) to cause cytotoxic cell death [7]. The overall flowchart of 5-ALA in clinical use is 
shown in fig. 1.4 [7].  
However, there are many limitation of 5-ALA in clinical use. The optimal excitation wavelength of 
PpIX is 405nm, but it has low permeability for visualizing superficial tumor cells at this short 
wavelength light. Even though 635nm wavelength excitation light can penetrate deeper into the 
tissue, PpIX has very weak absorption at this wavelength light. PpIX fluorescence is affected by 
autofluorescence as well. These limitations of 5-ALA induced PpIX often lead to inappropriate 
power delivery for PDT leasing to inadequate cytoxicity in tumor tissue or substantial toxicity in 
healthy tissue. Superficial PpIX may also lead to incomplete tumor removal due to inaccurate 
estimation of tumor extent. Dr Achilefu has developed a near-infrared fluorescence probe LS301 
that has been shown to be highly cancer targeted [9]. LS301 can target different types of covering 
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breast cancer, lung cancer, pancreatic cancer etc [8]. The absorption and emissions spectrum o 
LS301 and PpIX are shown in fig 1.5 [7,8,9]. This project aims to investigate whether LS301 
fluorescence can improve PpIX PDT and increase surgical removal of brain tumors. 
(a) (b)  
Figure 1.5 Absorption and Emission spectrum of LS301 and PpIX, (a) LS301 spectrum and (b) PpIX 
fluorescence spectrum. 
 
1.4 Fluorescence lifetime imaging 
 
To minimize the interference of autofluoresence in PpIX fluorescence detection, we introduced 
fluorescence-lifetime imaging (FLIM) in this project. FLIM is relaying on the differences in the 
exponential decay rate of the fluorescence emission [10]. The mechanism of FLIM is shown in fig 
1.6 [10]. Fluorescence lifetime is independent to the concentration of compounds. 
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(a) (b)  
Figure 1.6 Fluorescence lifetime mechanisms  
 
The fluorescence lifetime of 5-ALA induced PpIX has been identified to be around 6 ns and other 
intermediate metabolites generate a significantly different fluorescent lifetime at around 1ns, which 
shown in fig.1.7 [11]. Therefore, 5-ALA induced PpIX fluorescence is distinguishable from 
autofluoresence by FLIM.  
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Figure 1.7 PpIX and autofluorescence lifetime 
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Chapter 2 
 
Materials and Methods 
 
2.1 Cell lines 
 
U87-MG human brain glioblastoma cells (ATCC, HTB-14, Mamassas, VA, USA) were cultured in 
Eagle’s minimum essential medium (RMPI 1640) with L-glutamine (Lonza, Poetmouth, NHUSA), 
1% penn-strep and 10% fetal bovine serum (PAA, Westborough, MA, USA) at 37°C and 5% CO2. 
DBT glioblastoma were cultured in DMEM with L-glutamine (Lonza, Poetmouth, NH, USA), 1% 
penn-strep and 10% fetal bovine serum (PAA, Westborough, MA, USA) at 37°C and 5% CO2. 
2.2 In vitro fluorescence measurement 
2.2.1 Confocal microscope 
 
Seeded 30,000 cells in 8 chamber culture slides in medium overnight. Treated cells with 4mM 5-
ALA only, 4uM LS301 only and both 4mM 5-ALA and 4uM LS301 for 6 hours, respectively. PpIX 
and LS301 fluorescence were measured using Olympus confocal microscope fv1000, 60X 
magnification at 488/ 630 nm and 780/800 nm, respectively. Fluorescence intensity was calculated 
by ImageJ.  
2.2.2 Microplate reader 
 
5-ALA (Sigma-Aldrich, St. Louis, MO, USA) was dissolved in phosphate buffered saline (ref.) to 
make a 50.0mM solution. 100 uL of cells were plated in each well in black wall and clear bottomed 
96 well plates with a density of 10,000 cells per well. Cells were treated with 5-ALA solution at 50.0, 
25.0 12.5, 6.25, 3.13, 1.56, 0.78, 0.39, 0.20, 0.05, 0.02 mM for 3 hours. Cells per well were treated 
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with 4mM 5-ALA and 1uM LS301 (Achileful Optical radiology lab, Wustl, MO, USA) for 0, 8h, 16, 
24, 32, 48, 56, 64, 72 hours, respectively.  96 wells plates with treated cells were measure using a 
Microplate Reader, with a standard 405nm excitation/ 635nm emission filter to detect PpIX 
fluorescence and 780nm excitation/ 830nm emission filter to detect LS301 fluorescence, 
respectively.  
2.2.3 Fluorescence analysis on FLIM 
 
30,000 cells were seeded in the dish culture and cells were treated with 8mM 5-ALA for 24 hours. 
4uM LS301 was further used to treat the cells for another 6 hours. Control wells, as well as 5-ALA 
and LS301 treated only were also prepared. PpIX fluorescence was recorded by 519LP excitation 
and LS301 fluorescence was recorded by 790/LP filter.  The resolution was set to 400 X 400 pixels. 
Fluorescence analysis was then merged by ImageJ. 
 
2.3 Subcutaneous and orthotopic mice models 
2.3.1 Small animal imaging 
 
Around 1.5 million DBT and U87 tumors cells were implanted subcutaneously into the right flank 
of BalbC and Nude mice models, respectively. Orthotopic 87-MG mice were offered by LeMoyne 
Habimana-Griffin at ORL center, WUSTL. After the tumor grew big enough, 100 uL of 60uM 
LS301 was injected intravenously. After 16 hours, 100uL of 50mg/mL 5-ALA dissolved in PBS was 
injected intraperoneally (IP). FMT, Brucker carestream multiple spectral fluorescence imaging and 
Pearl Trilogy small imaging system were used to obtain fluorescence images. Mice were imaged by 
channel 700 (excitation 685nm, emission 720nm) and channel 800 (excitation 785nm, emission 820 
nm) on Pear imager at dorsal position and ventral position, respectively. PpIX fluorescence were 
also imaged by Brucker imaging system using 420nm excitation/ 600nm emission, 510nm 
excitation/600nm emission, 630nm excitation/700nm emission, respectively. And LS301 
fluorescence detection on Brucker used 780nm excitation/830nm emission. PpIX and LS301 
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fluorescence calibration was set on FMT by 635 nm excitation/ 650-670nm emission and 790nm 
excitation/ 805+ nm emissions, respectively.  
2.3.2 Photodynamic therapy protocol 
 
Five nude mice were used for PDT experiment. All five mice were implanted with U87 cells. After 
the tumor grown for three weeks, injected 100uL 60uM LS301 in M4 and M5 and then injected 
100uL, 50mg/mL 5-ALA after 16h hours. M2 and M3 were only injected with 100uL 50mg/mL 5-
ALA. M1 was used as control without any treatment. 660nm laser was used to irradiate the tumor 
spot after 6 hours post injection of 5-ALA in M2, M3, M4 and M5. The distance between LED 
lends and mice tumor was set to 10 cm to generate an intensity of 72mW/cm2 irradiation. Exposure 
time was 20 minutes [12]. The size of tumors was measured and recorded for 5 days.  
2.3.3 ImageJ analysis 
 
All the analysis of fluorescence intensity in vivo and in vitro experiments were analyzed by ImageJ. 
Data were plotted by using Prim’s algorithm. 
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Chapter 3 
 
Results and Discussion 
 
3.1 In vitro study  
 
3.1.1 LS301 has good uptake in DBT and U87 cells 
 
Initially, we identified the uptake of LS301 and 5-ALA in two cell models, U87 and DBT cells. U87 
is high grade IV human adult glioblastoma cell line and DBT is high grade IV mouse glioblastoma 
cell line, respectively.  PpIX fluorescence failed to be observed on the Confocal in our lab due to the 
absence of ideal 405nm/635nm excitation/emission filter. In addition, no significant difference of 
PpIX fluorescence between 5-ALA treated U87 and DBT cells and control cells under 
488nm/635nm, 580nm/640nm and 615 nm/715 nm filters on confocal (Fig. 3.1 a-f). PpIX 
fluorescence was even weak at the ideal 405nm/635nm excitation filter on confocal which offered 
by the Molecular Imaging Center at Washington University (Fig 3.1 g). LS301 fluorescence in DBT 
and U87-MG cells treated with 4uM LS301 for 6 hours were distinct on Confocal microscope by 
using 780nm excitation and 830 emission filters (Fig. 3.2). Thus, we made a conclusion that LS301 
has a better uptake in the two cell lines than 5-ALA.  
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(a)  (b)  
(c)    (d)  
(e)   (f)  
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(g)  
Figure 3.1 PpIX fluoresence in U87 cell line by Confocal microscope .(a, c, e) Fluoresence signal in control 87-
MG cells at 488nm exictation/ 635nm emission filter,  580 nm exictation/ 640nm emission filter 615nm 
exictation/ 715 nm emission filter, repectively. (b,d,f), PpIX fuorescnece in U87-MG cells treated with 0.4 mM 
5-ALA for 6 hours at 488nm excitation/ 635nm emission filter filter, 580 nm exictation/ 640nm emission filter 
615nm exictation/ 715 nm emission filter, repectively. (g) PpIX fuorescnece in U87-MG cells treated with 0.4 
mM 5-ALA for 3 hours at 405 nm excitation/ 635nm emission filter. 
 
(a)  (b)  
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(c)  (d)  
Figure 3.2 LS301 fluoresence in U87 and DBT cell lines by Confocal microscope. (a) Fluorescnece in untreated 
DBT cells (control) and (b) LS301 fluoresence (red) in DBT cells treated with 4uM LS301 for 6 hours by 785 
nm/830nm filter. (c) Fluorescnece in untreated U87 cells (control) and (d) LS301 fluoresence (red) in U87 cells 
treated with 4uM LS301 for 6 hours by 785 nm/830nm filter. 
  
3.1.2 LS301 and PpIX fluorescence quantification by microplate 
reader 
 
We further studied the uptake of LS301 and 5-ALA in DBT and U87 cell lines by using microplate 
reader. The microplate reader provides the best choice of excitation and emission filter, 
405nm/635nm, for PpIX fluorescence. The results showed that the optimum concentrationof 5-
ALA for both DBT and U87-MG was 4mM. Also, DBT cells had a better uptake of 5-ALA than 
U87 cells. (Fig. 3.3).  At the concentration of 5-ALA at 4mM, PpIX fluorescence was over 30 times 
higher in DBT cells than untreated cells but only two fold higher in U87 cells over untreated cells. 
The optimum LS301 concentration was 4uM. LS301 was produced in Dr. Achilefu’s lab and it was 
sparing used in the experiment. The highest concentration of LS301 for quantifying the LS301 
fluorescence was 5uM. For both DBT and U87 cell lines, LS301 fluorescence intensity in 0.4uM 
LS301 treated cells was already 10 folds higher than untreated cells. From the fig. 3.3 and fig. 3.4, 
both DBT and U87 cells demonstrated better uptakes of LS301 than 5-ALA. The uptake of LS301 
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and 5-ALA over time was also studied. The error bar in the fig 3.5 is scientifically large. The time 
course experiment will be repeated in the future.  
(a) (b)  
Figure 3.3 Optimum concentration of 5-ALA for inducing PpIX is 4mM. (a), (b) PpIX fluorescence intensity at 
increasing 5-ALA concentrations in DBT and U87 cell lines for 3 hours, respectively. Excitation at 405nm and 
emission at 635nm on microplate reader were used for PpIX fluorescence. 
 
(a) (b)  
Figure 3.4 Optimum concentration of LS301 is 4uM. (a), (b) LS301 fluorescence intensity at increasing LS301 
concentration in DBT and U87 cell lines for 3 hours, respectively. Excitation at 780 nm and emission at 830 nm 
on microplate reader were used for PpIX fluorescence. 
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Fig 3.5 LS301 and 5-ALA uptake time course recorded on microscope reader. LS301 fluorescence intensity 
change at 780nm/830nm filter 72 hours in DBT cells (solid red line) and U87 cells (dash red line) after treated 
with 1uM LS301, respectively.  PpIX fluorescence intensity at 405nm/635nm filter change over 72 hours in 
DBT cells (solid green line) and in U87 cells (dash green line) after treated with 4mM 5-ALA, respectively. 
3.2 Fluorescence lifetime imaging analysis 
 
Autofluoresence in DBT and U87 at 510nm excitation filter gave the average fluorescence life time 
at around 2ns. Average fluorescence life time for both cell lines treated with 8mM 5-ALA was 
around 4ns (Fig 3.5 and Fig 3.7).  The fluorescence lifetime of PpIX is slightly different from the 
study of Jennifer A. Ressell et al because the autofluorescence is not removed in the FLIM 
measurement. The LS301 average fluorescence life time was around 1ns. (Fig 3.5 and Fig.3, 7) Image 
J analysis showed the co-localization of LS301 and PpIX. (Fig 3.6 and Fig 3.8). To further confirm 
the co-localization of LS301 and PpIX in cells, the bio-distribution of LS301 and PpIX in different 
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organelles will be studied in the future. Overall, LS301 and PpIX show co-localization at some sites 
inside of U87 and BDT cells. 
(a) (b)  
(c) (d)  
(e) (f)  
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Figure 3.5 Fluorescence lifetime for LS301 and PpIX in DBT cells. (a) and (b): Fluorescence lifetime image 
and lifetime histogram of LS301 in DBT cells, receptively. (c) and (d): Fluorescence lifetime image and 
lifetime histogram of PpIX in DBT cells at 510nm excitation light filter, receptively. (e) and (f) Fluorescence 
lifetime image and lifetime histogram of autofluorescence in DBT cells at 510nm excitation light filter, 
receptively. 
(a) (b) (c)  
Figure 3.6 LS301 and PpIX fluoresence in same DBT cells. (a) LS301 fluoresence in DBT cells (b) PpIX 
fuoresence in DBT cells. (c) overlap of LS301 and PpIX fluoresence in DBT cells on imageJ. 
(a) (b)  
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(c) (d)  
(e) (f)  
Figure 3.7 Fluorescence lifetime for LS301 and PpIX in U87 cells. (a) and (b): Fluorescence lifetime image and 
lifetime histogram of LS301 in U87 cells, receptively. (c) and (d): Fluorescence lifetime image and lifetime 
histogram of PpIX in U87 cells at 510nm excitation light filter, receptively. (e) and (f) Fluorescence lifetime 
image and lifetime histogram of autofluorescence in U87 cells at 510nm excitation light filter, receptively 
(a) (b) (c)  
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Figure 3.8 LS301 and PpIX fluoresence in same U87 cells. (a) LS301 fluoresence in U87 cells (b) PpIX 
fuoresence in U87 cells. (c) overlap of LS301 and PpIX fluoresence in U87 cells on imageJ. 
3.3 LS301 and PpIX co-localization in mice model 
 
3.3.1 Subcutaneous DBT mice  
 
Identification of LS301 and PpIX fluorescence was then confirmed in mice modes with DBT 
tumors implanted subcutaneously. Three different excitation/emission filtered lights were used on 
Bruker multi-spectra fluorescence imaging system, 420nm/600nm, 510nm/600nm and 
630nm/700nm, respectively. 5-ALA induced PpIX fluorescence was only detectable by 630nm 
excitation filtered light (Fig 3.9). This phenomenon can be explained by the permeability of light 
though tissue: longer wavelength light is capable for deeper detection. Merging the PpIX 
fluorescence at 630nm excitation filter and the LS301 fluorescence at 760nm excitation light by 
using ImageJ analysis which showed the overlap of LS301 and PpIX fluorescence in subcutaneous 
DBT mouse at tumor area. (Fig 3.10).  PpIX fluorescence was recorded at different time after the 
injection of 5-ALA, which is shown in fig. 3.11. There is not significantly change over time by 
420nm/600nm and 510nm/600nm filters. However, PpIX fluorescence was increased with 
increased time after 5-ALA inject and reached at maximum after the skin was deflected at the DBT 
tumor area (Fig. 3.11).  In addition, PpIX fluorescence of biodistribution by the three different 
filters also indicates that 630nm/700nm filter is the optimal choice for visualizing PpIX fluorescence 
in vivo (Fig 3.14). Figure 3.12 shows the overlap of LS301 and PpIX fluorescence at the tumor area 
after skin deflected. Biodistribution of PpIX and LS301 in organs show that LS301 and 5-ALA 
induced PpIX mainly accumulate in the DBT tumor tissue and so as to overlap of LS301 and PpIX 
in the tumor tissue (Fig. 3.13). Besides, high fluorescence in tumor and low fluorescence in muscle 
means high contrast. The tissue-to-muscle ratio of LS301 in Table 3.1 is two folds higher than PpIX 
(630nm/700nm). This proves that LS301 has higher contrast which could be potentially used to 
guide PpIX imaging surgery. 
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(a) (b) (c)  
Figure 3.9 PpIX fluoresence was not detectable at 420nm/600nm filtered light (a), 510nm/600nm filtered light 
(b) and 630nm/700nm filtered light (c), respectively. 
 
(a)   (b)  (c)  
Figure 3.10 LS301 and PpIX fluoresence overlap in subcutaneous DBT mouse. (a) PpIX fluoresence (green) by 
630nm/700nm filtered light (b) LS301 fluoresence (red) by  760nm/700nm filtered light. (c) Merged LS301 and 
PpIX fluorescence by Image J. 
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Figure 3.11: 5-ALA induced PpIX fluorescence intensity at different time by three different excitation/emission 
filters, 420nm/ 600nm (purple), 510/600nm (green) and 630nm/700nm (orange), repectively. PpIX fluoresence 
intensity after the skin deflected over the tumor area was also shown. 
(a)  (b)   (c)  
Figure 3.12 LS301 and PpIX fluoresence overlap in subcutaneous DBT mouse after skin deflected. (a) PpIX 
fluoresence (green) by 630nm/700nm filtered light (b) LS301 fluoresence (red) by  760nm/700nm filtered light. 
(c) Merged LS301 and PpIX fluorescence by Image J. 
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(a)  (b)  (c)  
Figure 3.13 Biodistribution of PpIX and LS301 fluorescence in subcutaneous DBT mouse. (a) PpIX 
fluoresence (green) by 630nm/700nm filtered light (b) LS301 fluoresence (red) by  760nm/700nm filtered light. 
(c) Merged LS301 and PpIX fluorescence by Image J. On the left column, from the top to bottom: heart, lung, 
spleen, kidney and liver, respectively. On the right column, from the top to bottom: skin, muscle, brain, tumor 
and blood, respectively. 
 
Figure 3.14 5-ALA induced PpIX fluoresence biodistribution by three different excitation/emission filters, 
420nm/ 600nm (purple), 510/600nm (green) and 630nm/700nm (orange), repectively.  
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LS301 and PpIX also shows co-localization at some sites in the DBT tumor tissue slice of 
subcutaneous DBT mouse. The reason that LS301 fluoresence is very weak is that most of LS301 
had been cleared by mouse after six days post injection of LS301. H&E staining confirmed the 
tissue cells which have fluorescence are tumor cells. 
 
(a) (b) (c)  
Figure 3.15 LS301 and PpIX fluoresence in tumor tissue slice of subcutaneous DBT mouse. (a) LS301 
fluorescence (red) under CY5 channel on Epi-fluoresence microscope. (b) PpIX fluorescence (green) under 
FITC channel on Epi-fluoresence microscope. (c) H&E staining of the tissue slice of interest.  
 
Ex/Em (nm/nm) 420/600 510/600 630/700 760/830 
Tumor-to-muscle ratio 1.36 2.36 10.8 23.8 
 
Table 3.1 Tumor-to-muscle ratio of fluorescnece at different filters.   
 
We also tried to use Pearl imager system to check PpIX fluorescnece. In fig. 3,16, PpIX fluorescece 
is not distinct by channel 700 on Pearl imager after 7hours injection of 5-ALA.  This can be 
explained that PpIX has very weak absoption at 685 nm excitation wavelength. Sencond injection of 
5-ALA was performed. The PpIX flurescence was recorded in 24hours. At 24 hours post injection 
of 5-ALA, weak PpIX signal on channel 700 is shown in fig. 3.18. PpIX fluorescence is more 
distinct after the skin was deflected at the tumor area. The pearl imager system also confirmed the 
colocalization of LS301 and PpIX in subcutaneous DBT mouse (fig. 3.20) 
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(a) (b) (c) (d)  
Figure 3.16 PpIX fluorescence is not obvious at  4h (a), 5.5h (b), 6h (c) and 7h (d) post injetion of 5-ALA on 
subcutaneous DBT mouse by channel 700 on Pearl imager. The excitation wavalength is 685nm and emission 
wavelength is 720nm on channel 700. 
(a) (b) (c) (d)  
Figure 3.17 LS301 fluorescence is obvious at  4h (a), 5.5h (b), 6h (c) and 7h (d) post injetion of 5-ALA in 
subcutaneous DBT mouse by channel 800 on Pearl imager. The excitation wavalength is 785nm and emission 
wavelength is 820nm on channel 800. 
(a) (b) (c) (d)   
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Figure 3.18 PpIX fluorescence is obvisous at 24h post injection of 5-ALA and at tumor area with skin deflected. 
Fluorescnee under channel 700 at 2hours PI (a),  9 hous PI (b), 24 hours PI (c) of 5-ALA in subcutaneous DBT 
mouse and deflected skin (d)  by channel 700 on Pearl imager. The excitation wavalength is 685nm and 
emission wavelength is 720nm on channel 700. 
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Figure 3.19 5-ALA induced PpIX fluoresence intensity at different time by channel 700 on Pearl imager. PpIX 
fluoresence when the skin was deflected was recorded as well. 
(a) (b)  (c)  
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d) (e)  (f)  
Figure 3.20 co-localization of LS301 (red channel 800)and PpIX (green channel 700) were analyzed by Pearl 
imager. 
 
Overall, the best excitation and emission filter for observing PpIX fluoresence in subcutanous 
mouse mode is 630nm/700nm. And the PpIX fluoresence started to be distinct after 9 hours from 
100uL 50mg/mL 5-ALA injection. Without the block of skin, PpIX fluoresence intensity reached 
maximum. Furthermore, overlap of LS301 and PpIX fluoresence indicated the colocalizatio of 
LS301 and PpIX in subcutanous DBT mouse model. 
3.3.2 Subcutaneous and Orthotopic U87 mice  
 
630/700nm excitation and emission filter has been confirmed as the best choice for detecting PpIX 
fluorescence in subcutaneous mice model. The previous study in vitro also showed that U87 does 
not has a good uptake of 5-ALA and LS301 as DBT cells. Thus it is reasonable that PpIX 
fluorescence was not detectable on Brucker imaging system when the tumor tissue was not exposed 
under the 630nm excitation light. PpIX fluorescence became distinct in subcutaneous U87 mouse 
after its skin was deflected under 630nm/700nm. However, 630/700nm filter did not work well for 
orthotopic U87 mice after the skull open. In contrast, PpIX fluorescence signal in orthotopic U87 
mouse was visualized by 510nm/600nm filter (fig 3.24). PpIX fluorescence ratio of tumor to muscle 
is less than 1 which means that PpIX is a low contrast for subcutaneous U87 mouse (table 3.2). The 
LS301 fluorescence ratio of tumor to muscle in subcutaneous U87 mouse was over 3.5. Apparently, 
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LS301 serves as a higher contrast comparing to PpIX. Thereby, LS301 has the potential to be play 
an important role in guiding PpIX imaging surgery for glioblastoma tumor patients. 
(a)  (b)  (c)  
Figure 3.20 LS301 and PpIX fluoresence overlap in subcutaneous U87 mouse after skin deflected. (a) PpIX 
fluoresence (green) by 630nm/700nm filtered light (b) LS301 fluoresence (red) by  760nm/700nm filtered light. 
(c) Merged LS301 and PpIX fluorescence by Image J. 
(a) (b) (c)  
Figure 3.21 Biodistribution of PpIX and LS301 fluorescence in subcutaneous U87 mouse. (a) PpIX fluoresence 
(green) by 630nm/700nm filtered light (b) LS301 fluoresence (red) by  760nm/700nm filtered light. (c) Merged 
LS301 and PpIX fluorescence by Image J. On the left column, from the top to bottom: heart, lung, spleen, 
kidney and liver, respectively. On the right column, from the top to bottom: skin, muscle, brain, tumor and 
blood, respectively. 
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Figure 3.22 LS301 and PpIX fluorescne intensity at different post injection hours. LS301 fluorescnece is 
indicated by solid red line and PpIX fluorescence is indicated by solid green line, respectively.  
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Figure 3.23: 5-ALA induced PpIX fluoresence biodistribution by three different excitation/emission filters, 
PpIX fluorescence is shown in green bar and LS301 fluorescence is shown in red bar , repectively. 
 
Ex/Em (nm/nm) 630/700 760/830 
Tumor-to-muscle ratio 0.78 3.09 
Table 3.2 Tumor-to-muscle ratio of fluorescnece at different filters.  PpIX fluorescence ratio of tumor to musle 
is recoded by 630nm/700nm filter, and LS301 ratio is recorded by 760nm/830nm filter, respectively. 
 
(a)   (b) (c)   (d)  
Figure 3.24 PpIX and LS301 fluoresence in orthotopic U87 mouse model. (a) PpIX fluoresence is weak by 
630/700nm filter on brucker imaging system. (b) PpIX fluorescence by 510/600 nm filter. (c) LS301 
fluorescence by 760/830nm filter. (d) Merged LS301 and PpIX in orthotopic U87 mouse by Image J analysis.  
(a)            (b)  
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(c)      (d)   
Figure 3.25 LS301 and PpIX fluoresence on FMT system. (a) and (c) represnet front view and side view of 
LS301 and PpIX fluorescence observed at 22 hours PI of LS301 and 6hours PI of 5-ALA by 790 channel and 635 
channel, respectively. (b) and (d) front view and side view of LS301 and PpIX fluorescence observed at 46 
hours PI of LS301 and 24 hours PI of 5-ALA by 790 channel and 635 channel, respectively. 
 
Pearl imager and Brucker imaging system only can provide 2D image. FMT, a small-animal 
fluorescence in vivo imaging system, was introduced to provide 3D reconstructed image. Channel 
790 (excitation 790nm/emission 805nm) was used to detect LS301 fluorescence. PpIX have a 
sbsorption peak at 635nm wavelength but a low fluorescence at 660nm emission filter. Thus, 
channel 635 (excitation 635nm/emission 660nm) still is not the best choice for PpIX fluorescence. 
LS301 and PpIX fluorescence co-localize in orthotopic U87 mousea at 22 hours LS301 and 6 hours 
5-ALA. But PpIX fluorescence is not shown at 24 hours PI of 5-ALA. In summary, LS301 and 
PpIX fluorescence still show co-localization in subcutaneous and orthotopic U87 mouse model. 
510nm/600nm filter on brucker gave higher PpIX fluorescence in orthotopic U87 mouse model 
rather than 630/700nm, the optimal protocol for subcutaneous mouse model. 
3.4 LS301 guided PpIX PDT in mice model 
 
3.4.1 PDT setup  
 
660nm wavelength laser was used to irradiate the tumor spot in the subcutaneous U87 mice model 
after 6h post injection of 100uL, 50mg/mL 5-ALA. The distance between LED len and mice tumor 
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was set to 10cm to achieve an irradiation intensity of 72mW/cm2. The exposure time was 20 
minutes [12]. The custom PDT setup in our lab is shown in fig. 3.26.  
  
Figure 3.26 PDT setup 
3.4.2 Tumor growth rate after PDT  
 
The tumor size calculation formula used to calculate subcutaneous tumor tissue sie is shown in 
equation 1 [13].  
V= 
(𝐥𝐨𝐧𝐠 𝐥𝐞𝐧𝐠𝐭𝐡)×(𝐬𝐡𝐨𝐫𝐭 𝐥𝐞𝐧𝐠𝐭𝐡𝟐) 
𝟐
                        Equation 1 
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Figure 3.27 tumor growth ratio after PDT on subcutaneous U87 mice model.  
 
Subcutaneous U87 tumors implanation in mouse M2 was failed. The tumor growth ratios of other 4 
subcutaneous U87 mice are shown in fig. 3.27. Tumor was continuouly growing in both 
subcutaneous U87 mice treated with PpIX PDTor LS301-PpIX PDT. This negative result might be 
caused by the limitation of PDT setup. In most research studies, 635nm laser provides the most 
efficient PpIX PDT and the ideal irradiation intensity is 100 mW/cm2. However, 660nm laser was 
used in our PDT trials and the PDT radiation power was not strong enough. But LS301 PpIX PDT 
showed restriction of tumor growth comparing to PpIX PDT in the absence of LS301. We might 
assume that LS301 may improve PpIX mediated PDT. 
3.5 Future plans 
 
In the next step, we will work in tracking LS301 and PpIX target sits in various organelles of brain 
cell lines. And we will perform PDT using 635nm laser to brain cell lines and mice models. Also, the 
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amount of mice is not sufficient in this thesis research study; thus, we will also repeat in-vivo study 
with more mice. 
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